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ABSTRACT 
The need for early detection of Alzheimer’s disease has been well established in previous 
literature. As technology has spread across all professional fields, computerized screening 
instruments for the early detection of Alzheimer’s disease have begun to draw attention. 
Research has noted that computerized screeners of dementia should be implemented in 
primary care physician offices, as the majority of elderly persons see their PCP more 
frequently than other health professionals. Specifically, self-administered computerized 
screening instruments that have acceptable psychometric sturdiness are needed for these 
offices. GrayMatters is a self-administered computerized screening measure that has 
previously been shown to have acceptable reliability and validity. The aim of this study 
was to reevaluate the concurrent validity of GrayMatters. Reevaluation was needed in 
order to compare GrayMatters to the Wechsler Memory Scale-IV, rather than the 
Wechsler Memory Scale-III as previous research had done, and due to population 
changes over time. In order to evaluate the concurrent validity of GrayMatters, archival 
data from 149 female participants and 102 male participants was gathered from the Texas 
Neuropsychology Clinic. Data sets included participants GrayMatters scores, Wechsler 
Memory Scale-IV scores, Mini-Mental Status Examination scores, Trailmaking A and B 
scores, Boston Verbal Fluency Test scores, as well as the participant’s age, gender, race, 
and level of education. GrayMatters scores were compared to scores from the WMS-IV, 
MMSE, Trailmaking A and B, and Boston Verbal Fluency Test in order to examine 
concurrent validity. Results indicate that GrayMatters scores were compatible with scores 
from all previously mentioned measures. These findings are important because they 
indicate that GrayMatters can be used as a screening instrument of Alzheimer’s disease 
that can be used to measure cognitive impairment and guide decisions regarding patient 
care.  
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CHAPTER I 
INTRODUCTION 
As the elderly population increases rapidly worldwide, Alzheimer’s disease has 
become a primary health care concern, impacting more than 5.5 million elderly 
Americans. Alzheimer’s disease is the sixth leading cause of death in the United States 
and is thought to be the third leading cause of death in the elderly (National Institute on 
Aging [NIA], 2017a). The rates of Alzheimer’s disease have grown substantially, and 16 
million Americans are expected to be impacted by 2050 (U.S. Department of Health and 
Human Services [DHHS], 2013). Alzheimer’s disease leads to an inability to carry out 
activities of daily living, difficulty with word finding, impaired judgment, and deficits in 
cognitive functioning (NIA, 2017b). Individuals with Alzheimer’s disease may live 
anywhere between three to ten or more years after diagnosis depending on factors such as 
age at diagnosis and treatment received (NIA, 2017a), but ultimately, Alzheimer’s 
disease is fatal. Early diagnosis of Alzheimer’s disease is critical, as it allows the patient 
to explore treatment options and begin treatment earlier. Unfortunately, many individuals 
suffering from memory loss do not seek out early neuropsychological evaluation; 
however, elderly individuals often schedule appointments with their primary care 
physician (PCP). Thus, dementia screening by the PCP is arguably the preferred option. 
The need to develop and implement valid, short dementia screening tests in PCP offices 
is fundamental to the early recognition and treatment of Alzheimer’s disease.  
2 
Diagnosis of Alzheimer’s disease 
The majority of individuals diagnosed with Alzheimer’s disease (AD) are 
diagnosed through a neuropsychological evaluation. A probable Alzheimer’s disease 
diagnosis can be established with 90% confidence through the utilization of medical 
history, laboratory tests, and neuropsychological evaluation (Humpel, 2011). 
Unfortunately, neuropsychological evaluation is costly, time-consuming, and potentially 
frustrating for the patient. Neuropsychological assessment may cost upwards of $1,000, 
an unfeasible amount for individuals on a fixed income and individuals with a low 
socioeconomic status. In spite of the complications with current diagnostic tools, 
Alzheimer’s disease diagnosis is critical for optimal patient care. 	
Current Diagnostic Methods	
 The Wechsler Memory Scale-IV (WMS-IV) is a widely used assessment of 
dementia that has received significant research support. Although the WMS-IV is the 
most widely used adult memory assessment (Pearson Clinical, 2009) and has been proven 
to have diagnostic and clinical usefulness, there are several limitations in using the 
WMS-IV for AD diagnosis. First, the WMS-IV is costly and time intensive to administer. 
Second, a test examiner with a thorough amount of training is required for administration. 
Third, several studies have noted the importance of considering education level when 
diagnosing AD (Bornstein, Chelune, & Priftera, 1989; Efklides et al., 2002; Farias, 
Harrell, Neumann, & Houtz, 2003), which the WMS-IV does not take into consideration. 	
 Screening instruments have been developed in order to combat the problems of 
cost and time-requirements associated with traditional diagnostic methods. Currently, the 
Mini-Mental Status Exam (MMSE) is the most widely used instrument to screen for 
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cognitive impairment (Brinkman et al., 2012). However, it has been shown to lack 
sensitivity with regards to mild cognitive impairment (Brinkman et al., 2012; Saxton et 
al., 2009). The Boston Verbal Fluency Test has also been used as a screening instrument 
for Alzheimer’s disease, as it measures disruptions in semantic memory, which has been 
associated with Alzheimer’s disease and other dementias (Maseda et al., 2014). 
Unfortunately, research suggests that education level impacts Boston Verbal Fluency 
Test scores (Maseda et al., 2014), which is not taken into consideration in administration. 
The use of computerized dementia screeners has been a recent focus of attention, as 
they provide a comprehensive assessment that combats the logistical and practical 
problems associated with traditional neuropsychological evaluation. 	
The Present Study	
 The present study evaluated the concurrent validity of a self-administered 
computerized assessment of dementia, developed by Dr. Samuel Brinkman, known as 
GrayMatters (Brinkman et al., 2012). To establish validity the current study compared 
GrayMatters to the WMS-IV, Trailmaking parts A and B, Boston Verbal Fluency Test, 
and the Mini-Mental Status Examination. Although GrayMatters has previously been 
shown to be a valid dementia screening measure (Brinkman et al., 2012), the present 
study sought to reevaluate validity for several reasons. First, the GrayMatters system 
needed to be validated in comparison to the Wechsler Memory Scale-IV, rather than the 
Wechsler Memory Scale-III. Second, as with the majority of scientific research, the 
current literature regarding the GrayMatters system derives from researchers who were 
involved in the construction of the test. The validity of GrayMatters was assessed by 
persons other than the test designer in the present study. Lastly, research also notes that 
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validity should be evaluated in matters of degrees, instead of absolute terms, so 
assessments must be reevaluated as the population changes over time (Bauer et al., 2012; 
Nunnally & Bernstein, 1994). 	
 The present work has implications for neuropsychologists, PCPs, and AD 
patients. Valid, short dementia screening measures are beneficial for both practitioners 
and patients as they save time, energy, and money by helping guide decision making as to 
who should seek in-depth neuropsychological evaluation. They may also provide care for 
typically underserved populations, as they are an option for individuals without 
insurance, have conservative costs, involve short administration times, and produce 
immediate results. Finally, results of this study may have important implications for 
future research. If patient’s attitudes towards dementia assessment in a PCP’s office 
versus a neuropsychology clinic were researched, the impact of patient setting preference 
on test scores could be explored. Examining the patient’s experience of dementia 
screening may help to guide decisions regarding optimal patient care.  
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CHAPTER II 
LITERATURE REVIEW 
Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that 
destroys brain cells, leading to a loss of memory and other brain functions (NIA, 2017b; 
U.S. Department of Health and Human Services [DHHS], 2013). Ultimately, AD is fatal. 
Problems with memory are generally the first sign of AD, but significant decline in other 
areas of cognitive functioning are also evident. AD is associated with visual-spatial 
issues, difficulty with word finding, and impaired judgment (NIA, 2017b). Eventually, 
AD leads to the inability to carry out daily tasks such as driving, cooking, and paying 
bills (NIA, 2017b). As the disease progresses, individuals may become anxious, worried, 
or violent. 	
 It is estimated that 5.5 million Americans aged 65 and older have Alzheimer’s 
disease, though many more individuals under the age of 65 also have the disease (DHHS, 
2013; NIA, 2017a). The number of AD cases is expected to climb significantly as the 
population continues to see a sharp increase in elderly individuals. The heightened rates 
of AD not only have negative effects on patients and caretakers, but also on communities 
and the economy (Brinkman et al., 2012). According to the Alzheimer’s Association, the 
cost of care for patients with AD in the United States in 2018 was $277 billion (2018). 
Over the next 40 years, caring for individuals with AD will cost taxpayers $20 trillion 
(DHHS, 2013). The extraordinary costs related to AD stem from payment for caretaker 
and living facilities, insurance coverage, and the high rates of co-occurrence of AD and 
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various diseases (DHHS, 2013).  Americans are in dire need of solutions to aid AD 
patients, caretakers, and the U.S. economy.  
Diagnosis of Alzheimer’s disease	
AD was officially recognized as a disease in 1984, but the AD diagnostic criteria 
were updated in 2011. The 2011 guidelines recognized that AD occurs on a spectrum 
with three stages: a preclinical stage with no symptoms, a middle stage consisting of mild 
cognitive impairment, and a final stage marked by dementia symptoms (Jack et al., 
2011). The revised diagnostic criteria also demonstrated that AD is more than a memory 
disorder and includes symptoms such as impaired word-finding ability and judgment 
(NIA, 2017b). One notable difference from the 1984 diagnostic criteria was the inclusion 
of biomarkers as indicators of underlying brain disease (Jack et al., 2011; NIA, 2017b). 
Biomarkers are “parameters (physiological, biochemical, anatomic) that can be measured 
in vivo and that reflect specific features of disease related pathophysiological processes” 
(Jack et al., 2011, p. 260). Key AD biomarkers include the buildup of 𝛽-amyloid protein 
in plaques and tau disposition in neurofibrillary tangles (Jack et al., 2011). Though the 
recognition of biomarkers has greatly enhanced the discovery and diagnosis of AD, the 
disease still cannot be truly diagnosed until autopsy (Mantzavinos & Alexiou, 2017; NIA, 
2017b). 	
Difficulty with AD Diagnosis	
Biomarkers have improved AD research and diagnosis, but recognition of 
biomarkers in individuals is not always a feasible option. The most notable issue in using 
biomarkers for diagnosis is that established biomarkers of AD are found in cerebrospinal 
fluid (Humpel, 2011). In order to evaluate an individual's biomarkers, he or she must 
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undergo lumbar puncture and collection of cerebrospinal fluid, which is painful for the 
individual and may lead to adverse side effects (Humpel, 2011). A further problem with 
the use of biomarkers as a diagnostic tool is that biomarkers have been primarily studied 
in Caucasian populations, and research is needed in diverse populations (Dubois, 
Padovani, Scheltens, Rossi, & Dell’Agnello, 2016; Jack et al., 2017). Currently, 
biomarkers are employed in research, but not in clinical care (Sullivan, 2018). 	
Neuropsychological evaluation is effective for diagnosing probable Alzheimer’s 
disease, but is costly, time-consuming, and potentially frustrating for the patient. A 
detailed neuropsychological assessment may take up to eight hours to complete when the 
assessment includes a thorough diagnostic interview and full neuropsychological test 
battery (University of North Carolina Department of Neurology, n.d.). The amount of 
time required to complete a neuropsychological assessment may be difficult for the 
individual due confusion, stress, and fatigue induced by testing. Evaluations are also 
costly, which is a source of concern for many patients. Individuals who reside in rural 
areas may be unable to obtain neuropsychological assessments, as professionals who are 
qualified to administer tests typically reside in urban areas. Professionals who are 
administering the assessment may also experience difficulty in gathering an accurate 
medical history from patients with memory deficits. In spite of the current complications 
with existing diagnostic tools, diagnosis of AD is critical for patient well-being. 
Specifically, early diagnosis is critical for AD patients to reap the greatest benefits from 
treatment.  
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Benefits of Early Diagnosis	
The advantages of early diagnosis of Alzheimer’s disease are numerous. Benefits 
may be emotional and interpersonal, medical, or financial (Boller & Barba, 2001; 
Brinkman et al., 2012; Fillit, H.M., Simon, E.S., Doniger, G.M., & Cummings, J.L., 
2008; Lees et al., 2014; Weimer & Sager, 2009). Individuals are first given a diagnosis of 
“probable AD” when they begin to show signs of mild cognitive impairment (Sullivan, 
2018). During this stage of AD, the individual may still function independently and may 
still drive, maintain employment, and be active socially (Alzheimer’s Association, 2018). 	
Emotional and Interpersonal Benefits  
Early diagnosis allows the patient and caretakers to plan for the future while 
symptoms are mild, so informed decisions can be made regarding treatment options, 
finances, and driving ability (Makizako et al., 2013; Saxton et al., 2009). Additionally, 
diagnosis during this stage allows patients and their families to explore education and 
support programs, leading to enhanced patient and caregiver well-being. (Alzheimer’s 
Association, 2018). Further, many patients experience a sense of relief following 
diagnosis. The majority of individuals with mild cognitive impairment recognize that 
they are having difficulty with memory, and as a result, the explanation of symptoms and 
presentation of a treatment plan may provide relief in many AD cases (Carpenter et al., 
2008; Portacolone, Johnson, Covinsky, Halpern, & Rubinstein, 2018). 	
Medical Benefits  
When an individual receives an early diagnosis of AD, he or she can implement 
various health behaviors to maintain their current level of cognitive functioning for a 
greater amount of time. For example, control of blood pressure, control of diabetes, and 
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smoking cessation will help to decrease the likelihood of a stroke, which leads to the 
progression of AD symptoms (Langa & Levine, 2014). The inclusion of aerobic exercise, 
mental stimulation, and social activity may also decrease the progression of cognitive 
decline (Langa & Levine, 2014). Unfortunately, the decline of a patient’s cognitive 
functioning typically goes unnoticed for several years, and by the time of diagnosis and 
treatment, the patient is too impaired to reap the full benefits of medication (Brinkman et 
al., 2012; Fillit et al., 2008). Early diagnosis also allows the patient and family members 
to consider different treatment options and decide what will be most beneficial for the 
patient. Although current medications cannot prevent or reverse the onset of AD, they 
can temporarily prolong cognitive functioning (Epperly, Dunay, & Boice, 2017). An 
early AD diagnosis also enhances an individual’s chances of participating in a clinical 
trial. Participating in trials with novel treatments may allow the patient to experience 
health benefits, often at no cost, while receiving high quality care, monitoring of 
symptoms, and education regarding AD (Alzheimer’s Association, 2011). Psychological 
benefits may occur from the knowledge that one is contributing to important research, 
even if novel medication proves ineffective for the patient (Alzheimer’s Association, 
2018). 	
Financial Benefits  
Early diagnosis of AD may result in reduction of health care costs both for the 
individual and for the national economy (Alzheimer’s Association, 2018). It is expected 
that the United States will spend more than $1.3 trillion in AD research and treatment by 
2050, but early diagnosis may alleviate some of the expense (Alzheimer’s Association, 
2018; Sullivan, 2018). If 88% of AD cases were diagnosed when they first began 
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showing signs of mild cognitive impairment, the US would save $231.4 billion in 
treatment and long-term care (Alzheimer’s Association, 2018; Sullivan, 2018). Savings 
would result from reduced Medicare and Medicaid expenditures, out-of-pocket expenses, 
and private insurance expenses (Alzheimer’s Association, 2018; Sullivan, 2018). Early 
diagnosis would aid in the savings through financial planning, early treatment options, 
and implementation of beneficial health behaviors.  
Current Diagnostic Methods 
WMS-IV 
The WMS-IV consists of seven primary subtests that measure auditory memory, 
visual memory, visual working memory, immediate memory, and delayed memory 
(Pearson Clinical, 2009). The delayed memory index has proven to be especially useful 
in aiding with AD diagnosis (Borstein, Priftera, & Chelune, 1989).  Research has noted 
that individuals diagnosed with AD perform significantly worse on the WMS-IV than 
healthy individuals (Efklides et al., 2002). Specifically, AD patients had lower scores in 
subtests measuring semantic memory, orientation, visual recognition, and new learning, 
which is consistent with current research on AD (Efklides et al., 2002). The WMS-IV has 
also been shown to have clinical utility in predicting AD patients’ ability to carry out 
activities of daily living (Farias et al., 2003). Individuals who received lower scores on 
the Logical Memory and Digit Span subtests of the WMS-IV were found to have greater 
difficulty in performing activities of daily living independently (Farias et al., 2003). 	
Screeners 
The Mini-Mental Status Exam (MMSE) is the most widely used screening 
instrument but has been shown to lack sensitivity with regards to mild cognitive 
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impairment (MCI) (Brinkman et al., 2012; Saxton et al., 2009). Research indicates that 
the sensitivity of the MMSE in detecting individuals with MCI who may progress to AD 
ranges from 27% (Buchave et al., 2008) to 89% (Arevelo-Rodriguez et al., 2015; 
Devanand et al., 2008). The specificity of the MMSE in detecting the progression of MCI 
to AD ranged from 32% (Buchave et al., 2008) to 90% (Arevelo-Rodriguez et al., 2015; 
Devanand et al., 2008). One study found that the MMSE was only able to correctly 
identify 54% of patients with MCI, and the MMSE also demonstrated ceiling effects 
(Hoops et al., 2009). The highly variable sensitivity and specificity of the MMSE indicate 
that a more consistent dementia screening instrument is needed. 	
The Boston Verbal Fluency Test has also been used as a screener for dementia. It 
has been shown to have a sensitivity of 78% when discriminating between healthy adults 
and adults with mild dementia (Gomez & White, 2006), but doesn’t consider the patient’s 
education level. Disruptions in semantic memory have been shown to be strongly 
correlated with Alzheimer’s disease and other dementias (Maseda et al., 2014). 
Additionally, both qualitative and quantitative aspects of the Boston Verbal Fluency Test 
are considered to be important in understanding the deteriorated cognitive processes of 
dementia patients; however, examining qualitative components of the Boston Verbal 
Fluency Test is subjective and time-consuming (Gomez & White, 2006). 	
Computerized tests have been developed to combat the problems with traditional 
dementia screening measures. (Ahn et al., 2010; Bauer et al., 2012; Dougherty et al., 
2010; Fowler, Saling, Conway, Semple, & Louis, 1997; Inoue, Jinbo, Nakamura, 
Taniguchi, & Urakami, 2009). Measures such as the Computerized Assessment of Mild 
Cognitive Impairment (Saxton et al., 2009), Mindstreams (Fillit et al., 2008), the 
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Computerized Self-Test (Doughtery et al., 2010), the Cognitive Assessment of Later Life 
Status (Zygouris & Tsolaki, 2014) and Cleveland Clinic Computerized Cognitive Battery 
(Rao, 2018) have been developed specifically for use by elderly persons. The aim of 
these computerized tests is to provide a comprehensive assessment that combats the 
logistical and practical problems associated with traditional neuropsychological 
assessment (Fillit et al., 2008). Computerized dementia assessments should strive to be 
simple and rapid, but maintain adequate sensitivity and specificity (Maruff et al., 2009).  
Benefits of Psychometric Diagnosis	
Alzheimer’s disease is primarily diagnosed through a primary care physician, 
neuropsychologists, geriatricians, or neurologists (National Institute on Aging [NIA], 
2017b). In order to diagnose AD, the clinician may conduct a diagnostic interview, 
administer tests of memory and problem solving, and perform brain scans and other 
medical tests to rule out other possible causes for the patient’s symptoms (NIA, 2017b). 
Extensive training and knowledge qualifications are expected of clinicians who may 
diagnose individuals with AD. Research indicates that for individuals to be considered 
competent in neuropsychology and neuropsychological assessment, he or she must have 
obtained graduate and professional training, have expert knowledge regarding the brain-
behavior relationship, have the required skills and knowledge regarding the 
neuropsychological assessments they may administer, be able to competently 
communicate neuropsychological findings and test results, and have the knowledge and 
skills needed for neuropsychological intervention (Hessen et al., 2017). 	
The majority of elderly persons obtain their health care solely from their primary 
care physician (PCP) and often fail to report problems with memory, leading to over half 
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of dementia cases going unnoticed (Fillit et al., 2008; Saxton et al., 2009). If a system 
were in place to aid PCPs in the early detection of cognitive impairment, it is estimated 
that the number of identified dementia cases would double (Brinkman et al., 2012; 
Saxton et al., 2009). Including a dementia screening as part of an elderly person’s routine 
physical examination would allow for better treatment for the patient, and better 
management of financial resources as only those who showed signs of impairment would 
be referred for lengthier, more costly neuropsychological assessment (Hammers et al., 
2012; Lees et al., 2014; Rao, 2018; Zygouris & Tsolaki, 2014). Since dementia screening 
by the PCP is arguably the preferred option, there is an increased interest in short 
screening tests (Fillit et al., 2008; Zygouris & Tsolaki, 2014). Short tests are preferable as 
they induce less fatigue for the patient and are able to be administered repeatedly, which 
is important in measuring cognitive decline over time (Hammers et al., 2012; Zygouris & 
Tsolaki, 2014). Specifically, low-cost, self-administered screening measures designed for 
use in a primary care office are needed to identify individuals in the preclinical stage of 
dementia, where pharmacologic interventions are most effective (Rao, 2018). 	
Determining baseline cognitive functioning in the elderly is also important for the 
diagnosis of AD. Obtaining baseline data regarding an individual's cognitive abilities in 
the areas of memory and executive functioning is especially important in recognizing 
onset of dementia (Brinkman et al., 2012). Research has indicated that baseline cognitive 
function is predictive of AD patients’ rate of decline in basic-care functioning (Atchison, 
Massman, & Doody, 2007). In fact, this longitudinal study discovered that concurrent 
neuropsychological assessment was better able to account for variance in patients’ self-
maintenance abilities than single measures of cognitive status (Atchison et al., 2007). 
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Obtaining baseline cognitive functioning scores by a PCP and repeating the assessment 
over time would be ideal for the recognition of cognitive decline, prediction of self-care 
functioning, and diagnosis of AD.  
Technology in AD Diagnosis	
Computerized dementia screening instruments are expected to become more 
widespread (Brinkman et al., 2012; Rabin et al., 2014; Wild et al., 2008). Specifically, 
self-administered computerized tests will increase rapidly in use as they have many cost-
effective and standardization benefits (Bauer et al., 2012; Brinkman et al., 2012). 
Advantages of self-administered computerized measures include: ability to be 
administered without highly-trained staff (Bauer et al., 2012; Brinkman et al., 2012; 
Rabin et al., 2014), administration of complex tasks in a standardized manner (Brinkman 
et al., 2012; Parsey & Schmitter-Edgecombe, 2013; Rabin et al., 2014; Wild et al., 2008), 
automated scoring and reporting (Bauer et al., 2012; Brinkman et al., 2012; Rabin et al., 
2014; Schatz & Browndyke, 2002), paperless record-keeping systems (Brinkman et al., 
2012), decreased examiner influence on responses (Bauer et al., 2012; Rabin et al., 2014; 
Wild et al., 2008), and increased accessibility in areas where there is a lack of 
psychological services (Bauer et al., 2012; Rabin et al., 2014). Although some may be 
concerned about the feasibility of older adults using self-administered technology, 
research demonstrates that older adults are welcoming of and able to respond to 
computerized self-administered tests (Collerton et al., 2007; Fillit et al., 2008; Wild et al., 
2008). Research indicates that dementia patients are accepting of technology, as long as 
there is minimal new learning required of them (Rosenburg, Wingard, Kottorp, & 
Nygard, 2012). 	
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GrayMatters	
 The current study utilizes a self-administered computerized assessment of 
dementia known as GrayMatters (Brinkman et al., 2012). Other computerized dementia 
assessments have been developed and show promise, which may lead some to question 
the need for another assessment. However, GrayMatters differs from previously 
developed measures in several ways. First, research suggests that computerized self-
administered measures designed to be used by elderly individuals should employ a touch-
screen computer monitor in order to decrease the difficulty of interactions between the 
patient and the computerized test (Tornatore, 2005). GrayMatters employs a touch-screen 
monitor in accordance with the current research. Second, according to the American 
Psychological Association (1999), computerized assessments should meet the same 
psychometric standards as examiner-administered tests (Bauer et al., 2012); however, 
many computerized tests lack an empirical foundation and psychometric sturdiness 
(Brinkman et al., 2012; Tierney & Lermer, 2010). GrayMatters has been previously 
established as an empirically supported computerized assessment (Brinkman et al., 2012). 
Third, GrayMatters presents directions both orally and visually, and administration 
requires only twenty minutes. The GrayMatters system was designed to measure memory 
and executive functioning, which have previously been established as key domains in 
identifying cognitive impairment and dementia. GrayMatters consists of a Visual 
Delayed Recognition Task (VDR) and a Delayed Alternation Task (DAT). 	
Visual Delayed Recognition Task  
Visual Delayed Recognition Task (VDR) was designed to measure visual memory 
(Brinkman et al., 2012). Research has previously established that visual memory tasks are 
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essential for recognizing cognitive decline and AD (Brinkman et al., 2012; Lee, 2010; 
Saunders & Summers, 2011). There is also some research that suggests that visual 
memory tasks may be more sensitive to the identification of mild cognitive impairment 
than verbal memory tasks (Alladi, S., Arnold, R., Mitchell, J., Nestor, P.J., & Hodges, 
J.R., 2006; Brinkman et al., 2012). The VDR task has a forced-choice format that 
measures an individual’s ability to obtain and retain new visual information. Images of 
objects are presented on the computer screen and patients are verbally instructed to study 
the pictures. The images are then removed from the screen, and one picture is presented 
to the patient while he or she is asked, through both verbal and written cues, to choose 
whether the picture (challenge picture) was one of the images just presented. The patient 
is cued to touch either the Yes or No button as their response to the question. VDR 
consists of 12 total trials. The first trial has a high likelihood of the patient responding 
correctly, with only two images presented simultaneously for five seconds and challenge 
items presented after a delay of five seconds. Eleven additional sets of images are shown 
on the computer screen, and each of these sets has four images presented simultaneously. 
In these sets, two challenge pictures are presented simultaneously after a five-second 
delay, and the participant again responds by selecting either the Yes or No button. There 
are an equal number of correct and incorrect challenge items presented to the patient. 
Trials 5 through 8 and trials 9 through 12 are comparable in difficulty level; however, in 
trials 9 through 12, patients are given simple distractor tasks during the delay interval to 
decrease the opportunity to replay the images in their mind. The distractor tasks are also 
completed via the touch screen monitor on the computer. A score is derived for VDR 
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based on the total number of correctly identified images on challenge trials, the number 
of false positive errors, and the number of correct responses on distractor tasks. 	
Delayed Alternation Task 
The Delayed Alternation Task (DAT) is a useful measure of executive 
functioning for computerized assessments (Brinkman et al., 2012) that was originally 
described by Hunter (1913). DAT is a problem-solving task with paradigm shifts. There 
are four tasks, each consisting of different rules, which are presented via the computer to 
the patient. First, a picture of two hands is shown on the monitor. The pictures of the 
hands are mirror images of the same hand, which ensures that the pictures are equated 
visually. The patient is asked to touch the hand that he or she believes a coin can be 
found under. After the participant responds, the hand is flipped to either show a coin or 
an empty hand. After a 10-second delay, which is consistent with traditional DAT 
paradigms, the set of hands are presented again, and the patient is again prompted 
visually and orally to select which hand he or she believes the coin is under. The visual 
cue is presented in text version on the computer screen, and the same instructions are 
presented in the visual and oral format. In the first task of DAT, the Delayed Alternation 
rule is followed which consists of the coin being placed in the opposite hand after a 
correct response and remaining in the same hand after an incorrect response. The 
response is correct on the first trial regardless of which hand the patient selected. There 
are 25 individual trials unless a patient responds correctly to five trials sequentially, 
which denotes that the patient reached the success criterion. 	
After 25 trials, which is the failure criterion, or reaching the success criterion, the 
patient begins a second task that utilizes a non-alternating rule. This rule causes the coin 
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to remain in the same hand during all trials. The patient’s first response is again 
considered correct regardless of which hand is chosen. The criteria for success and failure 
are the same under this rule as the previous rule. The previously used delay period 
between trials is discontinued under this rule and all subsequent rules in order to shorten 
the overall assessment time, as the primary interest in these rules involves the patient’s 
ability to shift cognitive sets after learning the first rule. 	
During the third task, the hands are replaced by shapes. This rule is called the 
Shape Alternation rule and uses a blue circle and a red square as stimuli. The patient is 
instructed to select which shape the coin is under. Again, the patient’s first response is 
always correct, and the coin is switched to the opposite shape after a correct response and 
remains under the same shape after an incorrect response. The locations of the shapes, 
either left or right side of the computer monitor, vary based on a predetermined sequence. 
The same success and failure criteria are implemented in this rule. 	
The fourth and final task is the Side Alternating rule and uses the same shapes as 
the previous task. In this rule the coin is moved to the opposite side of the screen after a 
correct response and is left on the same side of the screen after an incorrect response. 
Again, the location of the shapes varies depending on the predetermined sequence of the 
25 trials. Success and failure criterion are the same as previous rules. The scores for DAT 
are determined by the number of rules for which the patient meets success criteria, total 
number of correct responses over all four rules, and the number of perseverative errors. A 
perseverative error is an error on consecutive responses.  
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Early Psychometric Data 
In an earlier psychometric study of GrayMatters, all recruited participants were 
able to complete the screening test, and no statistically significant differences between 
racial or ethnic groups were discovered (Brinkman et al., 2012). The previous research 
had more female than male participants, and impaired individuals were significantly older 
than unimpaired individuals. The education level of the impaired group was lower than 
the education level of the unimpaired group by 0.8 years. The analyses indicated that 
unimpaired participants had significantly better scores than the impaired participants in 
total number of correct responses in VDR, the number of false positive errors, and the 
number of correct responses on distractor tasks. Expected differences in the DAT section 
were also discovered. The VDR test-retest reliability ranged from 0.72 to 0.74 (p<.001) 
and DAT correlation coefficients ranged from 0.37 to 0.54 (p<.001).  Correlations 
between the WMS-III and VDR were statistically significant. Statistically significant 
were also found between measures of executive functioning. The previous study did not 
follow up with participants to determine how many individuals were diagnosed with 
dementia.  
Present Study 
The current study will reevaluate the concurrent validity of GrayMatters. That is, 
the validity of GrayMatters will be established by comparing GrayMatters scores to 
scores of the WMS-IV, Trailmaking parts A and B, Boston Verbal Fluency Test, and the 
Mini-Mental Status Examination. While GrayMatters has previously been established as 
a reliable and valid measure (Brinkman et al., 2012), the current study will examine 
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validity with newer versions of measures that have been developed and with the current 
population. 
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CHAPTER III 
METHODS 
Participants	
 Data for the present study was collected through archival records from the Texas 
Neuropsychology Clinic in Abilene, Texas. The most recent 102 men and 148 women to 
have completed a neuropsychological assessment and be diagnosed with Alzheimer’s 
disease were included in the study. This method of selecting subjects was chosen for two 
reasons. First, a primary goal of the present study was to validate GrayMatters with 
current populations, so utilizing recent data was imperative. Second, the current study 
sought to validate GrayMatters with both males and females, as earlier psychometric 
studies lacked proportionate gender participation. Permission to access the data sets was 
obtained through the Texas Neuropsychology Clinic, and all records remain the private 
record of the Clinic. The data collected from each of the participants consisted of their 
GrayMatters, WMS-IV, MMSE, Boston Verbal Fluency Test, and Trailmaking A and B 
scores. All data sets were cleansed of the subject’s identity. Personal information 
included with the data set consisted of the subject’s age, gender, and highest level of 
education. Data sets were cleared of any identifying information by the office manager of 
the Texas Neuropsychology Clinic and sent electronically to the researcher. 	
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Measures	
GrayMatters  
The present study utilized GrayMatters as a self-administered computerized 
assessment of Alzheimer’s disease. GrayMatters employs two tasks: Visual 
DelayedRecognition and Delayed Alternation (Brinkman et al., 2012). The two tasks 
measure visual memory and executive functioning (Brinkman et al., 2012). Example 
exercises of GrayMatters include finding a coin under a set of hands based on a pattern 
and viewing images and identifying them after a delay (Brinkman et al., 2012). Specific 
details regarding Visual Delayed Recognition and Delayed Alternation tasks can be 
found in the GrayMatters section of the literature review. Early psychometric studies of 
GrayMatters suggest test-retest reliability ranging from 0.37 (DAT Rules Correct) to 0.74 
(VDR Distractor Correct), and statistically significant correlations between measures of 
executive functioning (Brinkman et al., 2012). 	
WMS-IV  
The WMS-IV was included as part of the data set in the current study as it is a 
widely used assessment of Alzheimer’s disease. The WMS-IV consists of seven primary 
subtests that measure auditory memory, visual memory, visual working memory, 
immediate memory, and delayed memory (Pearson Clinical, 2009). The WMS-IV has 
been found to have internal consistency ranging from 0.83-0.90 and test-retest 
correlations ranging from 0.50-0.73 (Pearson Clinical, 2009). 	
MMSE  
The MMSE was included as part of the collected data as it is currently the most 
widely used dementia screener (Brinkman et al., 2012; Saxton, 2009). The MMSE is a 
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30-item questionnaire that assesses an individual’s orientation to date and time, attention 
and calculation abilities, and capacity to follow commands (Folstein, Folstein, & 
McHugh, 1975). Example items include “What is the year?” and “Repeat the phrase ‘No 
ifs, ands, or buts.’” (Folstein et al., 1975). Reported degrees of the MMSE’s sensitivity 
and specificity have varied greatly. Early psychometric data suggested that the MMSE 
had both adequate reliability and validity (Folstein et al., 1975); however, more recent 
data has found inconsistent degrees of sensitivity and specificity (Arevelo-Rodriguez et 
al., 2015; Buchave et al., 2008; Devanand et al., 2008; Hoops et al., 2009). 	
Trailmaking A and B  
The Trailmaking tests were included in the study, as they have been used 
extensively in neuropsychological assessment and are a measure of an individual’s 
executive functioning (Brinkman et al., 2012). Part A of Trailmaking involves the patient 
drawing lines to connect circled numbers in numerical order as quickly as possible 
without making mistakes (Salthouse, 2011). Part B involves the patient drawing lines to 
connect circled numbers and circled letters while alternating numerical and alphabetical 
order as quickly as possible without making mistakes (Salthouse, 2011). Trailmaking test 
parts A and B have been shown to have high reliability with retest reliability of part A 
ranging from 0.76-0.89, and retest reliability of part B ranging from 0.86-0.94 (Wagner, 
Helmreich, Dahmen, Lieb, & Tadic, 2011). 	
Boston Verbal Fluency Test 
The Boston Verbal Fluency Test was included as part of the data set in the current 
study due to research noting the importance of semantic network deterioration in the 
detection of Alzheimer’s disease (Maseda et al., 2014). The Boston Verbal Fluency Test 
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involves asking a participant to name as many animals as possible in sixty seconds 
(Gomez & White, 2006). Although the Boston Verbal Fluency Test may be scored with 
both qualitative and quantitative components, only quantitative data was used in the 
present study. The quantitative variable of the Boston Verbal Fluency Test is scored by 
totaling the number of correct responses for animal that the participant is able to name in 
sixty seconds (Gomez & White, 2006). The sensitivity of the Boston Verbal Fluency Test 
in detecting dementia has ranged from 67% (Sebaldt et al., 2009) to 77% (Radanovic et 
al., 2008). 	
Hypotheses	
The hypotheses guiding the statistical analyses for the present study were as 
follows: 1) GrayMatters Composite score will be significantly, negatively correlated with 
both the WMS-IV Delayed Memory Index and Visual Memory Index, 2) GrayMatters 
Composite score will be significantly, negatively correlated with MMSE score, 3) 
GrayMatters Composite score will be significantly, positively correlated with (a) 
Trailmaking A and B completion times and (b) Trailmaking A and B error rates, and 4) 
GrayMatters Composite scores will be significantly, negatively correlated with Boston 
Verbal Fluency Test score. Negative correlations were expected on Hypotheses 1, 2, and 
4 due to higher scores indicating impairment on GrayMatters Composite and lower scores 
indicating impairment on the WMS-IV Delayed Memory and Visual Memory Indices, 
MMSE, and Boston Verbal Fluency Test. Positive correlations were expected on 
Hypothesis 3 due to higher scores indicating impairment on all measures. 
25 
CHAPTER IV 
RESULTS 
The following sections detail the results of the analyses exploring the concurrent 
validity of GrayMatters when compared to well-established dementia screening 
instruments. Preliminary screens were conducted for missing data, and tests that do not 
have scores from all participants are noted. Finally, exploratory analyses on the influence 
of gender, race, age, and educational attainment are presented. 	
Description of Sample	
 The sample consisted of 40.6% male and 59.4% female participants. Participants 
had an average age of 76.6 (SD=8.1), and the majority (42.6%) of participants fell 
between the ages of 70 to 79. The sample was 90% Caucasian, and the majority of 
participants (34.3%) had a high school education. In order to account for any 
demographic variables, preliminary analyses were conducted. Further information 
regarding participant variables is presented in Table 1. 
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Table 1  
 
Participant Demographics 
    
Variable Percent       N  
 Gender 
  Female 
  Male 
 
59.4 
40.6 
 
149 
102 
 
Ethnicity 
  Caucasian 
  African-American 
  Hispanic  
  Pacific-Islander 
 
90.0 
2.0 
7.6 
0.4 
 
226 
5 
19 
1 
 
Education 
  Less than High School 
  High School 
  Some College 
  Bachelor Degree       
    or greater 
 
17.5 
34.3 
27.1 
21.1 
 
 
44 
86 
68 
53 
 
 
Age 
  Under 60 
  60-69 
  70-79 
  80-89 
  90+ 
 
3.2 
15.5 
42.6 
34.7 
4.0 
 
8 
39 
107 
87 
10 
 
Note. N=251 
Concurrent Validity 
 A total of 251 participants completed the GrayMatters procedures, WMS-IV, 
Trailmaking parts A and B, Boston Verbal Fluency Test, and MMSE. Although there 
were a total of 251 participants, only 21 participants completed the Visual-Working 
Memory portions of the WMS-IV due to age-cutoffs. Correlations between GrayMatters 
subtest scores and WMS-IV indices scores, Trailmaking parts A and B time to 
completion and errors, Boston Verbal Fluency Test scores, and MMSE scores were 
examined.  
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GrayMatters Scores and Wechsler Memory Scale-IV Indices  
Hypothesis 1 predicted that the GrayMatters composite score would be 
significantly, negatively correlated with both the WMS-IV Delayed Memory Index and 
Visual Memory Index. Low scores on the WMS-IV predict pathology while high scores 
on GrayMatters predict pathology; thus the negative relationship was predicted. A 
Pearson r correlation comparing GrayMatters composite score with WMS-IV Delayed 
Memory and WMS-IV Visual Memory supported this hypothesis. GrayMatters 
composite score was weakly correlated with WMS-IV Delayed Memory Index, r(249) = -
.21, p<.001, and moderately correlated with WMS-IV Visual Memory Index, r(249) = -
.372, p<.000. Additional analyses revealed a weak correlation between GrayMatters 
composite score and WMS-IV Auditory Memory Index, r(249) = -.255, p<.000, a 
moderate correlation between GrayMatters composite score and WMS-IV Immediate 
Memory Index, r(249) = -.414, p<.000, and a strong correlation between GrayMatters 
composite score and WMS-IV Visual-Working Memory Index, r(19) = -.618. p<.003. 
The correlations can be found in Table 2, and the findings suggest that GrayMatters 
composite score is consistent with WMS-IV indices scores.  
Table 2 
Correlations between GrayMatters Composite Score and WMS-IV Indices Scores 
GrayMatters Composite Score 
Auditory Memory    -.255**   
Visual Memory    -.372**   
Visual-Working Memory    -.618*       
Immediate Memory    -.414**            
Delayed Memory    -.210**             
*p<.005, **p<.001       
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Additional analyses exploring GrayMatters scores and WMS-IV Index scores 
reveal further correlations. A weak, significant, positive (the expected direction) 
correlation was discovered between GrayMatters Memory score and WMS-IV Visual 
Memory Index, r(249) = .241, p<.000. Additionally, GrayMatters Memory score was 
weakly correlated with WMS-IV Immediate Memory Index, r(249) = .198, p<.002, 
weakly correlated with WMS-IV Delayed Memory Index, r(249) = 132, p<.036, and 
moderately correlated with WMS-IV Visual-Working Memory Index, r(19) = .439, 
p<.046. These correlations can be found in Table 3 and suggest that GrayMatters 
Memory scores are consistent with Wechsler Memory Scale Index scores.  	
Pearson r correlations exploring the relationship between GrayMatters Executive 
Function scores and WMS-IV Index scores reveal additional significant correlations. 
GrayMatters Executive Function scores were weakly, positively (the expected direction) 
correlated with WMS-IV Visual Memory Index scores, r(249) = .173, p<.006, and 
weakly, positively (the expected direction) correlated with WMS-IV Immediate Memory 
Index scores, r(249) = .171, p<.006. The correlations can be found in Table 3, and results 
suggest that GrayMatters Executive Function scores are consistent with WMS-IV Visual 
Memory and Immediate Memory Index scores. 	
Analyses exploring GrayMatters Mental Control scores and WMS-IV Index 
scores suggest further significant correlations. A weak, positive (the expected direction) 
correlation exists between GrayMatters Mental Control scores and WMS-IV Auditory 
Memory scores, r(249) = .226, p<.000, WMS-IV Visual Memory scores, r(249) = .221, 
p<.000, and WMS-IV Delayed Memory scores, r(249) = .124, p<.049. In addition, a 
moderate, positive (the expected direction) correlation exists between GrayMatters 
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Mental Control scores and WMS-IV Immediate Memory scores, r(249) = .345, p<.000. 
All correlations can be found in Table 3, and findings reveal that GrayMatters Mental 
Control scores are consistent with WMS-IV Index scores. 	
Lastly, Pearson r correlations exploring the relationship between GrayMatters 
Overall score and WMS-IV Index scores reveal additional significant correlations. 
Positive (the expected direction), weak correlations exist between GrayMatters Overall 
scores and WMS-IV Auditory Memory, r(249) = .220, p<.000, and WMS-IV Delayed 
Memory, r(249) = .172, p<.006. Moderate correlations exist between GrayMatters 
Overall scores and WMS-IV Visual Memory scores, r(249) = .310, p<.000, and WMS-IV 
Immediate Memory scores, r(249) = .351, p<.000. A strong correlation exists between 
GrayMatters Overall scores and WMS-IV Visual-Working Memory scores, r(19) = .652, 
p<.001. Correlations can be found in Table 3 and suggest that GrayMatters Overall scores 
are consistent with WMS-IV Index scores.  
Table 3 
Correlations between GrayMatters Index Scores and WMS-IV Index Scores 
 GM 
Composite 
GM 
Memory 
GM Executive 
Function 
GM Mental 
Control 
GM 
Overall 
1. Auditory 
Memory -.255** .113 .102 .226** .220** 
2. Visual 
Memory -.372**     .241**  .173* .221** .310** 
3. Visual-
Working 
Memory 
-.618* .439 .400 .305 .652** 
4. Immediate 
Memory -.414**  .198*  .171* .345** .351** 
5. Delayed 
Memory -.210** .132 .088 .124 .172* 
*p < .01, **p < .001 
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GrayMatters Scores and MMSE Scores	
Hypothesis 2 predicted that GrayMatters Composite score would be significantly, 
negatively correlated with MMSE scores. A negative correlation was predicted due to 
higher GrayMatters Composite scores predicting pathology, while lower MMSE scores 
predict pathology. A Pearson r correlation comparing GrayMatters Composite scores 
with MMSE scores supported this hypothesis, which means that GrayMatters Composite 
scores are consistent with MMSE scores. GrayMatters Composite score was moderately 
correlated with MMSE scores, r(249) = -.488, p<.000. Additional analyses were 
conducted comparing the remaining GrayMatters Indices scores and MMSE scores. 
Weak, positive (the expected direction) correlations were found between MMSE scores 
and GrayMatters Memory scores, r(249) = .263, p<.000, and GrayMatters Executive 
Function scores, r(249) = .194, p<.002. Moderate, positive (the expected direction) 
correlations were found between MMSE scores and GrayMatters Mental Control scores, 
r(249) = .419, p<.000, and GrayMatters Overall scores r(249) = .432, p<.000. These 
correlations can be seen in Table 4, and findings reveal that GrayMatters Indices scores 
are consistent with MMSE scores.  
Table 4 
Correlations between GrayMatters Indices Scores and MMSE Score 
MMSE Score 
GM Composite    -.488**   
GM Memory    .263**   
GM Mental Control    .419**       
GM Executive Function    .194*            
GM Overall    .432**             
*p<.005, **p<.001       
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GrayMatters Scores and Trailmaking A and B Scores 
 Hypothesis 3 predicted that GrayMatters Composite score would be significantly, 
positively correlated with a) Trailmaking A and B completion times and b) Trailmaking 
A and B errors. A positive correlation was predicted due to pathology being predicted by 
higher scores by both GrayMatters Composite and Trailmaking parts A and B completion 
time and errors. A Pearson r correlation comparing GrayMatters Composite score with 
Trailmaking part A completion time and Trailmaking part B completion time support part 
a) of hypothesis 3. GrayMatters Composite score was moderately, positively correlated 
with Trailmaking part A completion time, r(246) = .474, p<.000, and moderately, 
positively correlated with Trailmaking part B completion time, r(222) = .316, p<.000. 
Findings suggest that GrayMatters Composite scores is consistent with both Trailmaking 
part A and B completion times. Correlations between GrayMatters Composite score and 
Trailmaking completion times can be seen in Table 5. 	
Additional analyses comparing the remaining GrayMatters Index scores with 
Trailmaking part A completion times reveal further significant correlations. Weak, 
negative (the expected direction) correlations exist between Trailmaking part A 
completion time and GrayMatters Memory scores, r(246) = -.224, p<.000, and 
GrayMatters Executive Function scores, r(246) = -.213, p<.001. Moderate, negative (the 
expected direction) correlations exist between Trailmaking part A completion time and 
GrayMatters Mental Control scores, r(246) = -.371, p<.000, and GrayMatters Overall 
scores, r(246) = -.407, p<.000. These results reveal that GrayMatters Index scores are 
consistent with Trailmaking part A completion times. Table 5 depicts these correlations. 	
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Additional Pearson r correlations comparing the remaining GrayMatters Index 
scores with Trailmaking part B completion times reveal further significant correlations. A 
weak, negative (the expected direction) correlation was found between Trailmaking part 
B completion time and GrayMatters Executive Function scores, r(222) = -.162, p<.015. 
Moderate, negative (the expected direction) correlations exist between Trailmaking part 
B completion times and GrayMatters Mental Control scores, r(222) = -.440, p<.000, and 
GrayMatters Overall scores, r(222) = -.303, p<.000. Findings reveal that GrayMatters 
Index scores are consistent with Trailmaking part B completion times, with the exception 
of GrayMatters Memory scores. All correlations can be viewed in Table 5. 	
Separate analyses comparing GrayMatters Composite score with Trailmaking part 
A errors and Trailmaking part B errors support part b) of hypothesis 3. GrayMatters 
Composite score was weakly, positively (the expected direction) correlated with 
Trailmaking part A errors, r(246) = .295, p<.000, and weakly, positively (the expected 
direction) correlated with Trailmaking part B errors, r(222) = .176, p<.008. These 
findings suggest that GrayMatters Composite score is consistent with both Trailmaking 
parts A and B error rates. The above correlations can be seen in Table 5. 	
Additional Pearson r correlations comparing the remaining GrayMatters Index 
scores and Trailmaking part A errors reveal further significant correlations. Weak, 
negative (the expected direction) correlations exist between Trailmaking part A errors 
and GrayMatters Memory scores, r(246) = -.179, p<.005, GrayMatters Mental Control 
scores, r(246) = -.193, p<.002, and GrayMatters Overall scores, r(246) = -.241, p<.000. 
Results reveal that all GrayMatters Indices, with the exception of GrayMatters Executive 
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Function, are consistent with Trailmaking part A errors. Correlations can be viewed in 
Table 5. 	
Analyses comparing the remaining GrayMatters Index scores and Trailmaking 
part B errors reveal additional significant correlations. Weak, negative (the expected 
direction) correlations exist between Trailmaking part B error rates and GrayMatters 
Executive Function scores, r(222) = -.199, p<.003, GrayMatters Mental Control scores, 
r(222) = -.243, p<.000, and GrayMatters Overall scores, r(222) = -.245, p<.000. Findings 
suggest that all GrayMatters Indices, with the exception of GrayMatters Memory, are 
consistent with Trailmaking part B errors. Correlations comparing all GrayMatters 
Indices and Trailmaking parts A and B completion times and errors can be found in Table 
5.  
Table 5 
Correlations between GrayMatters Index Scores and Trailmaking Scores 
 GM 
Composite 
GM 
Memory 
GM Executive 
Function 
GM Mental 
Control 
GM 
Overall 
1. Trailmaking 
A Time .474** -.224** -.213** -.371** -.407** 
2. Trailmaking B 
Time .316**    -.009        -.162* -.440** -.303** 
3. Trailmaking 
A Errors .295**    -.179*         -.116      -.193* -.241** 
4. Trailmaking B 
Errors .176*    -.002         -.199*      -.243** -.245** 
*p < .01, **p < .001 
GrayMatters Scores and Boston Verbal Fluency Test Scores 	
 Hypothesis 4 predicted that GrayMatters Composite scores would be 
significantly, negatively correlated with Boston Verbal Fluency Test score. A negative 
correlation was expected due to higher GrayMatters Composite scores predicting 
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pathology, while lower Boston Verbal Fluency Test scores predict pathology. A Pearson 
r correlation comparing GrayMatters Composite scores and Boston Verbal Fluency Test 
scores supported this hypothesis. GrayMatters Composite score was moderately, 
negatively correlated with Boston Verbal Fluency Test score, r(249) = -.443, p<.000. 
This finding suggests that GrayMatters Composite scores is consistent with Boston 
Verbal Fluency Test score. Additional analyses comparing the remaining GrayMatters 
Indices and Boston Verbal Fluency Test scores were conducted and revealed further 
significant correlations. Weak, positive (the expected direction) correlations exist 
between Boston Verbal Fluency Test scores and GrayMatters Memory scores, r(249) = 
.215, p<.001, and GrayMatters Executive Function scores, r(249) = .206, p<.001. 
Moderate, positive (the expected direction) correlations exist between Boston Verbal 
Fluency Test scores and GrayMatters Mental Control scores, r(249) = .420, p<.001, and 
GrayMatters Overall scores, r(249) = .419, p<.001. Correlations can be viewed in Table 
6, and results reveal that all GrayMatters Indices are consistent with Boston Verbal 
Fluency Test scores.  
Table 6 
Correlations between GrayMatters Indices Scores and Boston Verbal Test Score 
Boston Verbal Test Score 
GM Composite    -.443**   
GM Memory    .215**   
GM Executive Function    .206**       
GM Mental Control     .420**            
GM Overall    .419**             
*p<.005, **p<.001       
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Sample Characteristics	
 A total of 251 participants who had previously been diagnosed with Alzheimer’s 
disease by a neuropsychologist were included in the study. The sample consisted of more 
female (n=149) than male (n=102) participants. An independent samples t-test was 
conducted to investigate differences in scores between genders. Gender differences were 
examined due to research noting greater levels of female Alzheimer's disease cases than 
male cases (Alzheimer’s Association, 2019). In fact, the Alzheimer’s Association 2019 
Facts and Figures Report noted that two-thirds of Americans with Alzheimer’s disease 
are women (Alzheimer’s Association, 2019). Results indicated a statistically significant 
difference between male and female participants on the Boston Verbal Fluency Test. A 
Bonferroni post hoc test was conducted, and results revealed that male participants had 
significantly higher scores on the Boston Verbal Fluency Test than female participants. 
No statistically significant differences on other measures were noted. 	
The majority of the participants were Caucasian (n=226), followed by Hispanic 
(n=19), African-American (n=5), and Pacific Islander (n=1). Mean differences between 
groups were unable to be compared due to the small sample size of minority ethnic 
groups. Further exploration with more evenly distributed ethnic samples is needed to 
examine group differences by race.	
 The majority of the participants fell between the ages of 70-79, followed by 80-
89, 60-69, 90+, and under 60, respectively. Participants were categorized into groups by 
age due to the diverseness of participant ages, which ranged from age 50 to 96. Grouping 
participants by age allowed for investigation into group differences based on age. The 
number of participants in each age group can be seen in Table 1. A one-way analysis of 
  
36 
variance was conducted to investigate differences in scores among the measures 
described in the measures section and age. ANOVA results indicated statistically 
significant differences between age groups on the Auditory Memory portion of the 
WMS-IV, Immediate Memory portion of the WMS-IV, Trailmaking part B completion 
time, Trailmaking part B errors, Boston Verbal Fluency Test, GrayMatters Overall, and 
Mini-Mental Status Examination. A Bonferroni post hoc test was conducted to determine 
which age categories were significantly different. Results revealed that the age category 
of 80-89 had significantly lower scores than the age groups under 60 and 70-79 on the 
Auditory Memory portion of the WMS-IV. Another post hoc test indicated that the age 
categories of under 60 and 60-69 had significantly lower scores than the 80-89 age group 
on the Immediate Memory portion of the WMS-IV. In addition, the 60-69 age group had 
significantly lower scores than the 70-79 age group. A separate Bonferroni post hoc test 
was conducted, and results reveal that the age categories of 60-69 and 70-79 took 
significantly longer to complete Trailmaking part B compared to the age group of 80-89. 
Additionally, a post hoc test indicated that the age categories of 60-69 and 70-79 had 
significantly higher rates of errors on Trailmaking part B when compared to the age 
category 80-89. A different Bonferroni post hoc test was conducted and revealed that the 
age categories of 60-69 and 70-79 had significantly higher scores on the Boston Verbal 
Fluency Test in comparison to the 80-89 age group. In addition, the age groups of 60-69 
and 70-79 had significantly higher scores than the 80-89 age group on the Overall portion 
of GrayMatters. Lastly, the 70-79 age group had significantly higher scores than the 80-
89 and 90+ age groups on the Mini-Mental Status Examination.  
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Participants were grouped by education into four categories: less than high school 
(less than 12 years, n=44), high school graduate (12 years, n=86), some college (13-15 
years, n=68), and bachelor’s degree or higher (16+, n=53). A one-way analysis of 
variance was conducted to investigate differences in scores in measures previously 
described in the measures section and education level. ANOVA results reveal statistically 
significant differences among educational attainment categories on Trailmaking part A 
completion time, Trailmaking part B completion time, Trailmaking part B errors, and the 
Mini-Mental Status Examination. A Bonferroni post hoc test was conducted to determine 
which educational categories were significantly different. Results revealed that the 
education category less than high school education took significantly longer to complete 
the Trailmaking part A task than the education groups high school graduate and 
bachelor’s degree or higher. Additionally, the less than high school education group took 
significantly longer to complete the Trailmaking part B task than the high school 
graduate group. Results further indicated that the less than high school education group 
made significantly more errors than the high school graduate and some college education 
groups. Lastly, results reveal that the less than high school education group had 
significantly lower MMSE scores than the high school graduate, some college, and 
bachelor’s degree or higher groups.  
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CHAPTER V 
DISCUSSION 
Purpose and Findings	
 The purpose of the study was to evaluate the concurrent validity of GrayMatters 
and replicate the findings regarding validity from the pilot study (Brinkman et al., 2012). 
GrayMatters was compared to the WMS-IV, Trailmaking parts A and B, Boston Verbal 
Fluency Test, and the Mini-Mental Status Examination in order to establish concurrent 
validity in the present study. Previous studies supported the validity of GrayMatters 
(Brinkman et al., 2012), but the system needed to be validated alongside of the updated 
WMS and population changes over time. Additional analyses exploring gender, race, age, 
and education level differences among Alzheimer’s disease patients were also explored. 
The results of this study are first discussed in relation to study hypothesis; followed by 
study implications, study limitations, and directions for future research. 	
GrayMatters Scores and Wechsler Memory Scale-IV Indices Scores 	
 The Wechsler Memory Scale-IV is a widely used assessment of dementia that has 
significant research data to support its’ use in diagnosing Alzheimer’s disease. It is 
frequently used to make decisions regarding patient care including diagnosis, medication 
recommendations, and treatment effectiveness.  The present study found that 
GrayMatters Composite score is consistent with all WMS-IV Indices scores (Hypothesis 
1). Additionally, GrayMatters Memory score was consistent with all WMS-IV Indices 
scores, with the exception of the Auditory Memory index. GrayMatters Executive 
39 
Function scores are consistent with WMS-IV Immediate Memory and Visual Memory 
scores. The Mental Control portion of GrayMatters is consistent with all WMS-IV 
Indices scores, except for the Visual-Working Memory portion of the WMS-IV. Lastly, 
GrayMatters Overall scores were found to be consistent with all WMS-IV Indices scores. 
In other words, all GrayMatters scores are compatible with scores from the WMS-IV; 
however, GrayMatters Composite and Overall scores seem to be most comparable with 
WMS-IV Indices scores. These scores are likely most comparable with WMS-IV Indices 
scores as they incorporate data from all portions of the GrayMatters assessment. That is, 
both GrayMatters Composite and GrayMatters Overall integrate information regarding 
the participant’s performance on tasks involving memory, executive function, and mental 
control, so these scores accurately reflect the participant’s general mental functioning. 
The compatibility of WMS-IV Indices scores and GrayMatters scores demonstrates 
GrayMatters ability to measure cognitive impairment and guide decisions regarding 
additional patient care.  
GrayMatters Scores and MMSE Scores 	
 The Mini-Mental Status Examination is currently the most widely used dementia 
screening instrument that both medical and psychological practitioners use as a quick 
measure of changes in cognition and level of decline, as well as determine who should be 
referred for more extensive evaluation.  The present study found that GrayMatters 
Composite score is consistent with MMSE scores (Hypothesis 2). Additional analyses 
indicated that all GrayMatters scores (Composite, Memory, Executive Function, Mental 
Control, Overall) correspond with MMSE scores. The Composite, Mental Control, and 
Overall portions of GrayMatters had the highest rates of correspondence with MMSE 
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scores. That is, the scores from these portions of GrayMatters are most indicative of 
similar scores on the MMSE. The comparability of GrayMatters scores to MMSE scores 
demonstrates that GrayMatters could be used as a prompt dementia screening assessment 
to measure cognitive decline and make recommendations regarding patient care. 	
GrayMatters Scores and Trailmaking A and B Scores 	
 The present study supported the hypothesis that a) GrayMatters Composite score 
is consistent with Trailmaking parts A and B completion times, and b) GrayMatters 
Composite scores is consistent with Trailmaking parts A and B error rates (Hypothesis 3). 
All GrayMatters scores (Composite, Memory, Executive Function, Mental Control, 
Overall) correspond with Trailmaking part A completion times. Additionally, all 
GrayMatters scores, with the exception of Memory scores, are compatible with 
Trailmaking part B completion times. Surprisingly, GrayMatters Executive Function had 
the weakest correlation with Trailmaking part B completion times, which has previously 
been shown to be a good measure of executive functioning (Brinkman et al., 2012). 	
 GrayMatters Composite, Memory, Mental Control, and Overall scores were found 
to be consistent with Trailmaking part A error rates. All GrayMatters scores, with the 
exception of Memory scores, were compatible with Trailmaking part B error rates. Again 
surprisingly, of the scores that correlated with Trailmaking part B error rates, 
GrayMatters Executive Function had the lowest correlation rate. One possible 
explanation for the lower correlation rate could be that while GrayMatters Executive 
Function measures strictly aspects of executive functioning, such as rule acquisition and 
sequencing, GrayMatters Composite and Overall scores include all aspects of brain 
functioning, including executive function, mental control, and memory. 	
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GrayMatters Scores and Boston Verbal Fluency Test Scores 	
 Finally, the present study supported the hypothesis that GrayMatters Composite 
score is compatible with Boston Verbal Fluency Test scores (Hypothesis 4). In fact, all 
GrayMatters scores are consistent with Boston Verbal Fluency Test scores. Interestingly, 
GrayMatters Mental Control had one of the higher correlations with Boston Verbal 
Fluency Test scores, which supports the idea that both measure an individual’s ability to 
retrieve information while under a time restriction. GrayMatters Composite, Mental 
Control, and Overall scores were most highly correlated with Boston Verbal Fluency Test 
scores. In other words, the scores from these portions of GrayMatters are most indicative 
of similar scores on the Boston Verbal Fluency Test. 	
Sample Characteristics 
Differences in scores among participants of varying genders, races, education 
level and ages were examined. Differences regarding sample characteristics are as 
follows: (1)	Gender differences: On Boston Verbal Fluency Test male participants were 
able to name significantly more animals in one minute than female participants. This 
gender difference could be due to more female than male participants, which may have 
lowered the average female score. Females made up approximately 60% of the entire 
sample. (2)	Race differences: Differences in scores among racial groups were unable to 
be explored due to the small sample size of minority ethnic groups. Future exploration is 
needed to examine potential racial differences in scores. (3)	Education level differences: 
On the MMSE participants who had less than a high school education had significantly 
worse scores than participants who had a high school or greater education. This finding is 
unsurprising as the MMSE requires the participant to employ skills, such as following 
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multi-step commands, which are practiced frequently in both high school and college 
courses. On Trailmaking A and B, participants with less than a high school education 
took significantly longer to complete the task and made more errors than participants 
with a high school education or greater. These findings are unsurprising as Trailmaking 
requires the participant to engage in counting, alphabetizing, and rule-shifting skills that 
are practiced in both high school and college courses. (4)	Age differences: Participants in 
the 80-89 age group had significantly more impaired scores on the WMS-IV Auditory 
Memory, GrayMatters Overall, MMSE, and Boston Verbal Fluency Test when compared 
to younger age groups. These findings were not surprising as deficits involving memory, 
free recall, executive function, and mental control are expected to worsen with age in AD 
patients. Surprisingly, younger age groups had significantly more impaired scores than 
older age groups on the WMS-IV Immediate Memory, Additionally, younger age groups 
took longer to complete and made more errors on Trailmaking part B than older age 
groups. These unexpected age differences may be due to the smaller sample size of 
younger age groups. 	
Limitations	
 The results of the study should be interpreted with consideration to the unique 
characteristics of the sample. First, the similarity of the sample demographics limits the 
ability to generalize to the wider population. The vast majority of the participants were 
Caucasian, and all data was gathered from a single neuropsychology clinic, causing 
generalizations to other ethnic groups and geographic areas to be difficult. Another 
limitation of the study is the inability to validate GrayMatters in other languages. 
Although the GrayMatters system is available in Spanish, and data was gathered 
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regarding Spanish-speaking patients, there was a lack of WMS-IV data for Spanish-
speaking individuals. The established validity of GrayMatters can only be applied to the 
English version and should not be generalized to the Spanish version. 	
Future Directions	
 Evidence suggests that dementia screening by PCPs is preferable (Fillit et al., 
2008; Zygouris & Tsolaki, 2014), and while the GrayMatters system is in place in PCPs’ 
offices, no data has been gathered from these systems. It would be helpful to gather data 
from the systems in PCPs’ offices to confirm GrayMatter’s validity in other settings. 
Gathering data from these offices would also help determine how often PCPs choose to 
screen their patients and if they have criteria in place for which patients they screen. 	
It would also be advantageous to research patients’ attitudes towards dementia 
assessment in PCPs’ offices versus a neuropsychology clinic in order to explore any 
differences in patient preference for setting. Assessing patient attitudes would also allow 
for research regarding attitudes impact on test scores. For example, do patients who are 
anxious score worse than patients who are not anxious? 	
Data should be gathered from patients who have other forms of dementia in order 
to determine GrayMatters validity with regard to dementia in general. Patients with 
vascular dementia, Lewy-Body dementia, and unspecified dementias should be included 
in a future study to determine the full extent of the validity of GrayMatters.  
Future studies should also examine the education levels of the various age groups. 
Considering the level of education within the age groups could help to account for 
variability in scores. Additionally, the possibility of an interaction effect could be 
examined. 	
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Finally, GrayMatters’ predictive validity should be explored. Data should be 
gathered from both AD patients and non-AD patients who have taken the GrayMatters 
assessment in order to determine GrayMatters’ ability to predict AD diagnosis. This 
information would help both PCPs and neuropsychologists determine which individuals 
should be sent for a more thorough neuropsychological examination.  
Conclusion	
 The current study provides support for the validity of the GrayMatters system as a 
screener for Alzheimer’s disease. Specifically, the present study supported the hypotheses 
that GrayMatters Composite score is compatible with scores from the WMS-IV, 
Trailmaking parts A and B, Boston Verbal Fluency Test, and the MMSE. Additionally, 
scores from GrayMatters Memory, Executive Function, Mental Control, and Overall 
were also found to be consistent with various portions of the WMS-IV, Trailmaking parts 
A and B, Boston Verbal Fluency Test, and the MMSE. Overall, the current study 
demonstrates the concurrent validity of GrayMatters. 	
PCPs should be encouraged to include GrayMatters as part of their general 
wellness check-up for elderly patients. Including GrayMatters would allow PCPs to be 
aware of possible cognitive decline or memory deficits that patients may feel 
uncomfortable discussing or are unaware of. Neuropsychologists should also be 
encouraged to administer GrayMatters as a screening instrument prior to a full diagnostic 
evaluation. GrayMatters is a quick, affordable screening measure, and administering it 
first would allow neuropsychologists to save time, energy, and money. It would also 
allow patients to save time, energy, and money, as full neuropsychological evaluations 
are both time-consuming and costly.  Neuropsychological assessment may cost upwards 
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of $1,000, an unfeasible amount for individuals on a fixed income and individuals with a 
low socioeconomic status. The high cost of evaluation, which is a cause of great concern 
for many patients, should not be demanded until a valid screening instrument indicates a 
need for further assessment. Additionally, patients who lack insurance may not seek care 
due to the high cost of evaluation and would benefit from a low-cost screening 
instrument. GrayMatters can be used to benefit typically underserved populations due to 
its’ conservative cost, short administration time, and production of immediate results.   
Unlike traditional screening measures, GrayMatters is self-administered, so it 
requires little time out of the busy schedules of both practitioners and patients. 
Additionally, GrayMatters includes an interpretative report that can be used by 
professionals and also given to patients. The report is written clearly and offers 
suggestions specifically for the patient who was evaluated. Furthermore, the report is 
generated immediately so patients do not need to anxiously await results.  Finally, using 
GrayMatters as a dementia screening tool would allow for early detection of memory loss 
allowing patients to receive optimal care. The need for early diagnosis and intervention 
has been established, and the immediacy of results allows the practitioner and patient to 
make decisions regarding patient care in a timely manner. 	
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